Basophil Activation Test Application in Drug Hypersensitivity Diagnosis: An Empirical Approach

Paolo Marraccini, Patrizia Pignatti, Andrea Daposalcamo, Rossana Salimbeni, Dario Consonni

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The diagnosis of drug hypersensitivity reactions (DHRs) is based both on clinical history and in vivo tests, such as specific IgE and cutaneous tests, when available. Objectives: The aim of this work was to evaluate the basophil activation test (BAT) as a supplementary tool for drug challenges and drug allergy diagnosis. Method: We evaluated 204 outpatients reporting DHRs. Available serum-specific IgE drugs were determined and cutaneous tests were performed when appropriate. BAT was performed immediately after blood sampling. The expression of CD63 was evaluated with flow cytometry. The test was considered positive when CD63 expression was > 5% and the stimulation index (the ratio of the percentage of CD63-expressing cells with drug exposure/percentage of CD63-expressing cells with wash buffer) was > 2. Patients who reported mild to severe reactions and those with a discrepancy between clinical history and BAT underwent a challenge test. Results: The drugs that caused adverse reactions were mainly antibiotics (49%). Non-steroid anti-inflammatory drugs (NSAID) were cited as responsible for DHRs in 37%, with the remaining 14% being due to other drugs. BAT revealed a high specificity (92%) and low sensitivity for antibiotics (40%). For the suspected reactions to penicillin, both the in vitro tests supported 94% of the diagnoses. We also observed a high specificity in the case of challenge with NSAIDs (100% specificity). Conclusions: BAT is effective in discriminating adverse drug reactions, whilst only more critical cases require integrated evaluations and more complex clinical examinations. It is relevant that the concordance of anamnesis and in vitro tests reduce the need for challenge testing, limiting them to selected cases.

Original languageEnglish
Pages (from-to)160-166
Number of pages7
JournalInternational Archives of Allergy and Immunology
Volume177
Issue number2
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Drug Hypersensitivity
Basophils
Pharmaceutical Preparations
Skin Tests
Drug-Related Side Effects and Adverse Reactions
Immunoglobulin E
Anti-Bacterial Agents
Non-Steroidal Anti-Inflammatory Agents
Penicillins
Flow Cytometry
Buffers
Anti-Inflammatory Agents
Outpatients
Serum

Keywords

  • Basophil activation test
  • Drug allergy
  • Penicillins
  • β-Lactams

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Basophil Activation Test Application in Drug Hypersensitivity Diagnosis : An Empirical Approach. / Marraccini, Paolo; Pignatti, Patrizia; Daposalcamo, Andrea; Salimbeni, Rossana; Consonni, Dario.

In: International Archives of Allergy and Immunology, Vol. 177, No. 2, 01.09.2018, p. 160-166.

Research output: Contribution to journalArticle

@article{1ed5459e0358490b8a74253d5c1182ef,
title = "Basophil Activation Test Application in Drug Hypersensitivity Diagnosis: An Empirical Approach",
abstract = "Background: The diagnosis of drug hypersensitivity reactions (DHRs) is based both on clinical history and in vivo tests, such as specific IgE and cutaneous tests, when available. Objectives: The aim of this work was to evaluate the basophil activation test (BAT) as a supplementary tool for drug challenges and drug allergy diagnosis. Method: We evaluated 204 outpatients reporting DHRs. Available serum-specific IgE drugs were determined and cutaneous tests were performed when appropriate. BAT was performed immediately after blood sampling. The expression of CD63 was evaluated with flow cytometry. The test was considered positive when CD63 expression was > 5{\%} and the stimulation index (the ratio of the percentage of CD63-expressing cells with drug exposure/percentage of CD63-expressing cells with wash buffer) was > 2. Patients who reported mild to severe reactions and those with a discrepancy between clinical history and BAT underwent a challenge test. Results: The drugs that caused adverse reactions were mainly antibiotics (49{\%}). Non-steroid anti-inflammatory drugs (NSAID) were cited as responsible for DHRs in 37{\%}, with the remaining 14{\%} being due to other drugs. BAT revealed a high specificity (92{\%}) and low sensitivity for antibiotics (40{\%}). For the suspected reactions to penicillin, both the in vitro tests supported 94{\%} of the diagnoses. We also observed a high specificity in the case of challenge with NSAIDs (100{\%} specificity). Conclusions: BAT is effective in discriminating adverse drug reactions, whilst only more critical cases require integrated evaluations and more complex clinical examinations. It is relevant that the concordance of anamnesis and in vitro tests reduce the need for challenge testing, limiting them to selected cases.",
keywords = "Basophil activation test, Drug allergy, Penicillins, β-Lactams",
author = "Paolo Marraccini and Patrizia Pignatti and Andrea Daposalcamo and Rossana Salimbeni and Dario Consonni",
year = "2018",
month = "9",
day = "1",
doi = "10.1159/000490116",
language = "English",
volume = "177",
pages = "160--166",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Basophil Activation Test Application in Drug Hypersensitivity Diagnosis

T2 - An Empirical Approach

AU - Marraccini, Paolo

AU - Pignatti, Patrizia

AU - Daposalcamo, Andrea

AU - Salimbeni, Rossana

AU - Consonni, Dario

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background: The diagnosis of drug hypersensitivity reactions (DHRs) is based both on clinical history and in vivo tests, such as specific IgE and cutaneous tests, when available. Objectives: The aim of this work was to evaluate the basophil activation test (BAT) as a supplementary tool for drug challenges and drug allergy diagnosis. Method: We evaluated 204 outpatients reporting DHRs. Available serum-specific IgE drugs were determined and cutaneous tests were performed when appropriate. BAT was performed immediately after blood sampling. The expression of CD63 was evaluated with flow cytometry. The test was considered positive when CD63 expression was > 5% and the stimulation index (the ratio of the percentage of CD63-expressing cells with drug exposure/percentage of CD63-expressing cells with wash buffer) was > 2. Patients who reported mild to severe reactions and those with a discrepancy between clinical history and BAT underwent a challenge test. Results: The drugs that caused adverse reactions were mainly antibiotics (49%). Non-steroid anti-inflammatory drugs (NSAID) were cited as responsible for DHRs in 37%, with the remaining 14% being due to other drugs. BAT revealed a high specificity (92%) and low sensitivity for antibiotics (40%). For the suspected reactions to penicillin, both the in vitro tests supported 94% of the diagnoses. We also observed a high specificity in the case of challenge with NSAIDs (100% specificity). Conclusions: BAT is effective in discriminating adverse drug reactions, whilst only more critical cases require integrated evaluations and more complex clinical examinations. It is relevant that the concordance of anamnesis and in vitro tests reduce the need for challenge testing, limiting them to selected cases.

AB - Background: The diagnosis of drug hypersensitivity reactions (DHRs) is based both on clinical history and in vivo tests, such as specific IgE and cutaneous tests, when available. Objectives: The aim of this work was to evaluate the basophil activation test (BAT) as a supplementary tool for drug challenges and drug allergy diagnosis. Method: We evaluated 204 outpatients reporting DHRs. Available serum-specific IgE drugs were determined and cutaneous tests were performed when appropriate. BAT was performed immediately after blood sampling. The expression of CD63 was evaluated with flow cytometry. The test was considered positive when CD63 expression was > 5% and the stimulation index (the ratio of the percentage of CD63-expressing cells with drug exposure/percentage of CD63-expressing cells with wash buffer) was > 2. Patients who reported mild to severe reactions and those with a discrepancy between clinical history and BAT underwent a challenge test. Results: The drugs that caused adverse reactions were mainly antibiotics (49%). Non-steroid anti-inflammatory drugs (NSAID) were cited as responsible for DHRs in 37%, with the remaining 14% being due to other drugs. BAT revealed a high specificity (92%) and low sensitivity for antibiotics (40%). For the suspected reactions to penicillin, both the in vitro tests supported 94% of the diagnoses. We also observed a high specificity in the case of challenge with NSAIDs (100% specificity). Conclusions: BAT is effective in discriminating adverse drug reactions, whilst only more critical cases require integrated evaluations and more complex clinical examinations. It is relevant that the concordance of anamnesis and in vitro tests reduce the need for challenge testing, limiting them to selected cases.

KW - Basophil activation test

KW - Drug allergy

KW - Penicillins

KW - β-Lactams

UR - http://www.scopus.com/inward/record.url?scp=85053674634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053674634&partnerID=8YFLogxK

U2 - 10.1159/000490116

DO - 10.1159/000490116

M3 - Article

AN - SCOPUS:85053674634

VL - 177

SP - 160

EP - 166

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 2

ER -